# 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)

> **NCT04144413** · PHASE3 · COMPLETED · sponsor: **Santen SAS** · enrollment: 350 (actual)

## Conditions studied

- Dry Eye Disease With Severe Keratitis

## Interventions

- **DRUG:** Open-label Ikervis
- **DRUG:** Masked Ikervis
- **OTHER:** Vehicle Comparator: Masked Vehicle

## Key facts

- **NCT ID:** NCT04144413
- **Lead sponsor:** Santen SAS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-31
- **Primary completion:** 2023-07-14
- **Final completion:** 2023-07-14
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04144413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04144413, "3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04144413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*